It's nice to hear from you! I thought you had exited Geron before it slided back to where it was before!! Anyhow, you sound less optimistic now about hold "soon to be lifted" as you had thought before. My puzzle is what Scarlett and Geron staff are doing to justify the salary/remuneration they have been drawing now? There is nothing for them to do; No other product to work on, no further research to work on, the Ph 2 MF trial in limbo, and no more shareholder meetings or CCs!!! Are they all hunting sharks or what?!!!
Simply, the idiots screwed up by not collecting adequate data during the ET PV/melanoma trials, perhaps to save cost!! But, those idiots thought it was appropriate to squeeze hefty compensations for themselves from the cash-strapped company and put many well-deserved technicians and scientists on the street!! I think, Geron needs an overhaul of its upper management.
Geron? I consider Geron shares much more difficult to predict than Exel. The management is tight-lipped and has taken missteps. Of course, the company is sitting on a golden egg - Imetelstat. At $2.38. it's a good buy. But, you may also consider adding ACTC below 0.07.
Geron management sucks. It's not shareholder friendly and is inept. The management must be changed, especially Scarlett and Huh must be removed and replaced with more competent guys with much better foresight. With the compensations given to them, I am pretty sure their replacement as above shouldn't be difficult. They both must be fired for disastrous steps taken by them that did not and will not benefit shareholders.
Truth will ultimately prevail and Jakafi lobby will disappear. Of course, someone higher up at the FDA and a lot many at the MPN forum were infected with the Jakafi lobby virus and they even ridiculed Tefferi!! They all will cover their skin once Imetelstat wagon starts rolling. God bless America where such lobbies can have a widespread influence!!! Vested-interest influence and brainwashing are normal here!!!
The Street surely must be a WS manipulation paid agent. Articles appearing under its umbrella may be designed to help its secret clients who may be dictating what goes out. People shouldn't read what is printed under The Street umbrella. I do not even click open any article appearing under The Street name.
If you posted something and want to see latest responses, it's frustrating. It doesn't help you follow up. This is a board where posters exchange thoughts, not a Seeking Alpha list of posts. Just a stupid change.
(contd) You will see a huge-size buy pretty soon, followed by monkey traders, driving up the SP. If you miss to accumulate now, the SP may not reach this low level again unless, of course, the stupid Geron management screws up something else. Howewver, one thing is sure: Geron does sit on a breakthrough product!
A lot of the sellers were waiting to be qualified for the Asteria share distribution. Those guys are exiting and the monkey traders helped driving down the SP, creating an excellent opportunity for those who want to accumulate cheap now.
Frustration from expectation of a quick lift of the hold ! No news yet after 4 months of useless hold, showing sign of the FDA's displeasure with the Geron management!!!
Apparently End has exited or decided to remain silent! Irish is apparently frustrated by the worms taking over this board!! Good luck!
It's product development which includes all testing and studies required by the FDA, which the Geron management failed to do adequately for their ET/PV trials; however, the MF trial by Mayo was done to the FDA's satisfaction. Thus, without the Mayo's MF trial, this management would have sunk the product to oblivian!! These bozos have failed in both the product development and management of the company through its lack of foresight reducing this once high-ranking multiple-product clinical-stage company to a only-one-product company with a staff shrunk to just 40 or so and yet the CEO being paid a huge $2.3M annual compensation!! What a bloody management!!!
The board must hold a special meeting and evaluate how worth the positions given to both Scarlett and Huh have been and, if it finds that they haven't delivered what they were expected to, it must replace them both with really competent guys. The shareholders, at least retail long-holding ones, must begin enmass writing to the board for their replacement.
Black, barring a few, I do not care for others on this board who are either novices, temporary traders - most uneducated or self-appointed pundits who often make laughable or wrong assessments or small hedge-fund implants. Most are what I call monkeys. I simply post my thoughts for the benefit of those few I care to communicate. I do not give a damn about what all others think about me or my posts.